Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ECH in neoadjuvant HER2 positive breast cancer
NCT01388647Phase 2Terminated
- Sponsor
- Vector Oncology
- Start
- Aug 2011
- Primary completion
- Jun 2014
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label trial of eribulin in breast cancer, sponsored by Vector Oncology. Primary endpoint: Pathologic Response. Started Aug 2011; status: terminated.
02
Drugs
eribulin
03
Conditions
breast cancer
Beyond the preview
Go deeper on NCT01388647.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01388647.